In different cancer therapies cardiac biomarkers, such as troponin I and NT-proBNP were checked as good indicators of susceptibility to cardiac toxicity, however, in some cases, they are better investigated in treatment of specific type of chemotherapy such as trastuzumab or tysosine kinase inhibitors or mToR inhibitors (sirolimus, temsirolimus) [7]. The gene discussed is NPPB; the disease is cancer.